Advice

following a resubmission considered under the end of life and orphan process:

trabectedin (Yondelis®) is not recommended for use within NHSScotland.

Indication under review: for the treatment of adult patients with advanced soft tissue sarcoma, after failure of anthracyclines and ifosfamide, or who are unsuited to receive these agents.

Efficacy data are based mainly on liposarcoma and leiomyosarcoma patients.

Trabectedin, compared with an alkylating chemotherapy, increased progression-free survival but not overall survival in patients with advanced liposarcoma or leiomyosarcoma who had previously been treated with an anthracycline-based chemotherapy.  The submitting company did not present a sufficiently robust clinical and economic analysis to gain acceptance by SMC.

This advice takes account of views from a Patient and Clinician Engagement (PACE) meeting.

Medicine details

Medicine name:
trabectedin (Yondelis)
SMC ID:
SMC2210
Indication:

Treatment of adult patients with advanced soft tissue sarcoma, after failure of anthracyclines and ifosfamide, or who are unsuited to receive these agents. Efficacy data are based mainly on liposarcoma and leiomyosarcoma patients.

Pharmaceutical company
Immedica
BNF chapter
Malignant disease and immunosuppression
Submission type
Resubmission
Status
Not recommended
Date advice published:
09 December 2019